Endovascular NeuromoDulation Treatment fOr Heart Failure Patients (ENDO-HF)
NCT ID: NCT02633644
Last Updated: 2023-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
30 participants
INTERVENTIONAL
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of the BioVentrix PliCath HF System
NCT01568164
University of Michigan Advanced Heart Failure Tele-Monitoring and Flexible Diuretic Project
NCT02344342
European FIH Study - NeoChord Transcatheter Mitral Repair System for Symptomatic Mitral Regurgitation
NCT05425628
Stimulation of the Diaphragm in Patients With Severe Heart Failure Following Heart Surgery
NCT00769678
DuoCor 2 DOMINATE Study
NCT07233876
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treated with Harmony System
Implantation and activation of the Harmony endovascular neurostimulator
Harmony System
Percutaneous neuromodulation of the aortic wall
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Harmony System
Percutaneous neuromodulation of the aortic wall
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject should be receiving optimal medical treatment
* Subject signed and dated informed consent
Exclusion Criteria
* Subject diagnosed with severe aortic valve disease
* Subject has severe mitral stenosis
* Subject involved in any concurrent clinical investigation
* Subject with cerebral vascular accident or transient ischemic attack prior to enrollment
* Subject diagnosed with Marfan Syndrome
* Subject with moderate or severe chronic obstructive lung disease
* Subject is allergic to iodine or contrast media
* Subject with prior cardiac transplant or heart transplant candidate
* Subject with a life expectancy of less than 12 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Enopace Biomedical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Weiss, MD
Role: STUDY_DIRECTOR
Enopace Biomedical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
OLV Hospital
Aalst, , Belgium
University Hospital Center Zagreb
Zagreb, , Croatia
Hippokration General Hospital
Athens, , Greece
Rambam Healthcare Campus
Haifa, , Israel
Baruch Padeh Medical Center (Poriya)
Tiberias, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL-250
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.